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radiotherapy was US $412.14 (SD: US $46.52). The mean cost per patient in each 
clinical stage to chemotherapy was I: US $3166.99 (SD: US $2258.67), II: US 
$3843.45 (SD: US $1381.09), III: US $5254.36 (SD: US $922.43), IV: US $2500.40 
(SD: US $1323.60) and the non classiﬁed: US $2565.25 (SD: US $1356.95) p 0.551. 
CONCLUSIONS: The results show that in México, in more expensive the treatment 
to patients with non-hodgkin lymphoma in clinical stage III.
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OBJECTIVES: To describe costs associated to the treatment of different stages of 
breast cancer patients at the Social Security Mexican Institute (IMSS) from the health 
care payer’s perspective. METHODS: A cost study was elaborated. Resource use and 
cost data were obtained from hospital (second and tertiary levels) records of 313 of 
treated patients during July 2008 to February 2009 using the following inclusion 
criteria: women older than 16 years with breast cancer histological diagnosis who 
accepted to be included in the protocol through informed consent. Although, patients 
excluded were those who showed a second malignant neoplasm or incomplete infor-
mation. We calculate mean, median, 95% conﬁdence interval (95% CI) for each clini-
cal stage and statistical differences were estimated through ANOVA tests, p value 
<0.05 was considered signiﬁcant to show differences. RESULTS: The median total 
cost per patient was found in US $6135.38 (95% CI, US $4216.19–US $9737.19); 
the median cost per chemotherapy cycle was US $615.48 (95% CI, US $425.98–US 
$1456.63); all chemotherapy treatment resulted in US $2702.03, (95% CI, US 
$1456.36–US $5503.49) and median costs per patient with radiotherapy resulted in 
US $1260.78 (95% CI, US $421.34–US $1260.78). The mean cost per patient in each 
clinical stage with chemotherapy was: I: US $1830.80 (95% CI, US $686.21–
$2975.39); II: US $5143.41 (95% CI, US $3570.19–$6716.62); III: US $4079.77 
(95% CI, US $2739.86–$5419.68); IV: US $4907.21 (95% CI, US $672.11–$9142.31) 
and the non classiﬁed patients: US $5250.66 (95% CI, US $3360.94–$7140.40); p = 
0.401. CONCLUSIONS: The results showed that at the IMSS, it is more expensive 
the treatment of breast cancer patients in clinical stage II; however, the less expensive 
treatments resulted for patients in clinical stage I. In addition, the treatment of non 
classiﬁed patients were the second most expensive according to our results.
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OBJECTIVES: To describe cost associated to the treatment of different stages of 
colorectal cancer at the Social Security Mexican Institute (IMSS) from the health care 
payer’s perspective. METHODS: A cost study was made. Resource use and cost data 
were obtained from hospital (second and tertiary levels) records of 115 treated patients 
from July 2008 to February 2009 using the following inclusion criteria: patients older 
than 16 years with colorectal cancer histological diagnosis who accepted to be 
included in the protocol through informed consent. Although, patients excluded were 
those who showed a second malignant neoplasm or incomplete information. We 
calculate mean,standard deviation (SD), median, 25 percentil and 75 percentil for each 
clinical stage and statistical differences were estimated through ANOVA tests, p value 
<0.05 was considered signiﬁcant to show differences. RESULTS: The median total 
cost per patient was US $3,263.52 (US $2,111.29 to US $4,881.14), the mean cost 
per chemotherapy was US $484.16 (SD: US $113.95), mean cost to radiotherapy was 
US $402.40 (SD: US $57.20). The mean cost per patient in each clinical stage to 
chemotherapy was I: US $247.21 (SD: US $247.21), II: US $482.48 (SD: US $208.96), 
III: US $393.75 (SD: US $192.35), IV: US $986.17 (SD: US $631.59) and the non 
classiﬁed: US $386.88 (SD: US $105.18) p 0.521. CONCLUSIONS: The results show 
that in México, in more expensive the treatment to patients with colorectal cancer in 
clinical stage IV, the cheapest treatment was to patients in clinical stage I, the treatment 
to clinical stage II patients are the second most expensive according our results, prob-
ably associated to longer hospital stay.
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OBJECTIVES: Novel chemotherapies for metastatic breast cancer (MBC), such as 
bevacizumab, have the potential to extend progression-free survival but with a ﬁnan-
cial burden to health systems. We estimate the cost-effectiveness of bevacizumab in 
combination with paclitaxel as compared to paclitaxel alone from the perspective of 
the United States Medicare system. METHODS: We constructed a hybrid decision 
tree-Markov model to follow a cohort for ten years composed of 10,000 women ages 
65 and older with a diagnosis of MBC and no prior chemotherapy in the metastatic 
setting. Individuals in the model transitioned between three distinct states: stable 
disease, progressive disease, and death. Transition probabilities, cost and outcome 
data were obtained from clinical trials, published Medicare reimbursement rates, and 
the peer-reviewed literature. Incremental costs per quality-adjusted life year (QALY) 
were valued in 2009 US dollars. We discounted costs and survival at 3% per year. 
Deterministic and probabilistic sensitivity analyses tested the robustness of the model 
to variation in key parameters. RESULTS: In the base-case scenario, the bevacizumab 
plus paclitaxel arm had 22 additional days in quality-adjusted survival at an additional 
cost of $104,102 per patient, resulting in an incremental cost-effectiveness ratio 
(ICER) of $1.7 million/QALY. In the probabilistic sensitivity analysis, the ICER plane 
of 1,000 Monte Carlo simulation trials resulted in bevacizumab being more costly and 
more effective in 66.8% of samples and the dominated strategy in 34.1% of samples. 
In the deterministic sensitivity analysis, results were robust to changes in cost and 
utility parameters. Variation in time in progressive state and overall survival resulted 
in higher costs and slightly better outcomes; however, none of the sensitivity tests had 
positive ICERs below $50,000/QALY. CONCLUSIONS: Given the high cost in rela-
tion to its survival beneﬁts, it is unlikely that adding bevacizumab for MBC would be 
a cost-effective allocation of Medicare resources.
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OBJECTIVES: Cisplatin is a chemotherapeutic agent which is widely used and studied 
for multiple cancer types; however certain types of toxicity (ototoxicity, nephrotoxic-
ity and neurotoxicity) are associated with Cisplatin. Preclinical studies, performed on 
human testicular cancer cell lines, have indicated that combining Cisplatin with a Src 
Inhibitor (KX1–004) may signiﬁcantly mitigate toxicity related damage. To utilize the 
results from preclinical studies examining the beneﬁt of combining Cisplatin with 
KX1–004 in conjunction with cost of illness estimates from the literature to estimate 
the potential economic beneﬁts which could result from KX1–004 utilization. 
METHODS: Data from preclinical studies examining the toxicity limiting efﬁcacy of 
KX1–004 was combined with clinical and economic data from the literature with 
respect to the estimated cost of health care resources related to the speciﬁed toxic 
effects. This efﬁcacy and costing information was combined within a decision tree 
model to estimate the potential cost savings. RESULTS: The preclinical data indicates 
that KX1–004 may have a protective effect with respect to the neurotoxic, nephrotoxic 
(22% less damage) and ototoxic (82% less damage) effects. The Src inhibitor, when 
used alone and in conjunction with Cisplatin, exhibited the potential to slow tumor 
growth and maintain overall body mass. The economic modeling resulted in a poten-
tial per patient cost savings of $1633 resulting from mitigation of the ototoxic and 
nephrotoxic effects. CONCLUSIONS: Recent research has indicated that Cisplatin 
should be considered as a component of the standard therapy regimen for certain 
cancer types; however toxicity remains a signiﬁcant concern. When Cisplatin is used 
within a regimen which includes KX1–004, the beneﬁts may include decreased damage 
due to toxicity and an improvement in quality of life. The Src inhibitor may also 
provide a survival beneﬁt by enabling patients to remain on a regimen which includes 
Cisplatin.
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OBJECTIVES: Clinical trials have shown a statistically signiﬁcant disease-free survival 
beneﬁt of oxaliplatin or irinotecan based combination therapy for stage IV colon 
cancer. However, less is known regarding the comparative effectiveness and cost-
effectiveness of these agents among elderly patients. Whether the additional beneﬁt of 
these two agents is worth the additional cost for elderly Medicare recipients is particu-
larly policy relevant. METHODS: A cost-effectiveness analysis of oxaliplatin or iri-
notecan based combination therapy versus 5-ﬂuorouracil/leucovorin (5FU/LV) in 
patients aged 66 or older with stage IV colon cancer was performed from a US Medi-
care health care payer perspective. Survival and direct medical costs were estimated 
using patient-level data from the 1997–2007 surveillance, epidemiology, and 
end results (SEER)-Medicare datasets for patients diagnosed through 2005. Incremen-
tal cost-effectiveness ratio (ICER) was calculated and expressed as cost per life-year 
